Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Anus Neoplasms 3Squamous Intraepithelial Lesions 2Prostatic Neoplasms 2Papillomavirus Infections 2Neuroblastoma 2Liver Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2HIV Infections 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Bile Duct Neoplasms 2Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Smoldering Multiple Myeloma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Precancerous Conditions 1Pleuropulmonary blastoma 1Pancreatic Neuroendocrine Tumors (pNET) 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neurofibrosarcoma 1

Interventions

Lenalidomide 3daratumumab 2Dexamethasone 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Maintenance 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Smoldering Multiple Myeloma × Watchful Waiting × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡